Herpes Zoster News and Research

RSS

Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

AJMC addresses role of community pharmacies in boosting adult vaccination rates

A recent publication from The American Journal of Managed Care, the leading peer-reviewed journal dedicated to issues in managed care, addresses the role of community pharmacies in boosting adult vaccination rates in the United States.

17 Aug 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

FDA approves first oral medication for adults with moderately to severely active ulcerative colitis

The U.S. Food and Drug Administration today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis. Xeljanz is the first oral medication approved for chronic use in this indication.

30 May 2018

Shot may help reduce risk of shingles

Anyone who has had chickenpox or the chickenpox vaccine is at risk for the painful skin condition herpes zoster, more commonly known as shingles. Both diseases are caused by the varicella-zoster virus, which stays in the body after chickenpox clears and may reactivate later in life.

18 Feb 2018

CDC recommends new vaccine for shingles

Last month a U.S. Food and Drug Administration (FDA) advisory panel had voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline’s Shingrix.

25 Oct 2017

New shingles vaccine gets FDA panel votes

On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline’s Shingrix is on its way to FDA approval.

14 Sep 2017

Studies reveal strategies for using shingles vaccine in arthritis patients

New research indicates that the live varicella-zoster vaccine--which is given to protect against shingles--elicits robust immune responses in patients when administered several weeks prior to the start of treatment with the arthritis drug tofacitinib.

28 Aug 2017

Research reveals underlying reason for intense pain in patients with shingles

Chickenpox is a typical childhood illness. In most cases, it is benign, and the symptoms disappear within ten days. However, its causative agent, Varicella zoster virus (VZV), remains in the organism forever. In some cases, the virus can be reactivated years later, causing a different disease known as herpes zoster, or shingles.

24 Aug 2017

Shingles raises the risk for heart attack and stroke

Persons who have had chicken pox are prone to develop shingles with the Herpes zoster virus that lays dormant within them. A new study has shown that getting shingles - a painful skin condition caused by the virus could also raise the risk of heart disease such as heart attacks and strokes in individuals. The study was published in the Journal of the American College of Cardiology.

5 Jul 2017

Herpes Zoster News and Research

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

AJMC addresses role of community pharmacies in boosting adult vaccination rates

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

FDA approves first oral medication for adults with moderately to severely active ulcerative colitis

Shot may help reduce risk of shingles

CDC recommends new vaccine for shingles

New shingles vaccine gets FDA panel votes

Studies reveal strategies for using shingles vaccine in arthritis patients

Research reveals underlying reason for intense pain in patients with shingles

Shingles raises the risk for heart attack and stroke

Researchers evaluate trends in emergency room use and treatment costs for shingles

Important vaccines that should not be missed by adults, elders and pregnant women

NYU Langone-led study to examine longer-term use of suppressive antiviral medication to reduce shingles

New collaborative initiative seeks to develop interventions for optimizing adult vaccination rates

New collaborative initiative aims to improve adult immunization rates

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News